PipelineReview.com12h
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...
PipelineReview.com12h
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
PipelineReview.com12h
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
PipelineReview.com12h
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
OSAKA, Japan I March 11, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has ...
PipelineReview.com12h
Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines
BERKELEY, CA, USA I March 11, 2025 I Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, today ...
PipelineReview.com12h
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...
PipelineReview.com12h
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
SOUTH SAN FRANCISCO, CA, USA I March 11, 2025 I Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral ...
PipelineReview.com12h
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even ...